

Title	Effects of switching weekly alendronate or risedronate to monthly minodronate in patients with rheumatoid arthritis: a 12-month prospective study
Author(s)	Ebina, K.; Noguchi, T.; Hirao, M. et al.
Citation	Osteoporosis International. 2016, 27(1), p. 351-359
Version Type	AM
URL	https://hdl.handle.net/11094/93258
rights	
Note	

Osaka University Knowledge Archive : OUKA

<https://ir.library.osaka-u.ac.jp/>

Osaka University

Original Article

Effects of switching weekly alendronate or risedronate to monthly minodronate in patients with rheumatoid arthritis: a twelve-month prospective study

Authors

Kosuke Ebina, MD, PhD ^{a*}, Takaaki Noguchi, MD ^a, Makoto Hirao, MD, PhD ^a, Jun Hashimoto, MD, PhD ^b, Shoichi Kaneshiro, MD, PhD ^c, Masao Yukioka, MD, PhD ^d, and Hideki Yoshikawa, MD, PhD ^a

Affiliations

^a Department of Orthopaedic Surgery, Osaka University, Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan

^b Department of Rheumatology, National Hospital Organization, Osaka Minami MedicalCenter, 2-1 Kidohigashi, Kawachinagano, Osaka 586-8521, Japan

^c Department of Orthopaedic Surgery, Japan Community Health Care Organization, Osaka Hospital, 4-2-78 Fukushima ward, Osaka 586-8521, Japan

^d Department of Rheumatology, Yukioka Hospital, 2-2-3 Ukita, Kita-ku, Osaka 530-0021, Japan

1
2 19
3
4
5 20 ***Corresponding author**
6
7
8 21 Tel: +81 6 6879 3552; Fax: +81 6 6879 3559
9
10
11 22 E-mail: k-ebina@umin.ac.jp (K. Ebina)
12
13
14
15 23
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Abstract

Purpose

The aim of this prospective, observational study was to evaluate the effects of switching weekly alendronate (ALN 35 mg) or risedronate (RIS 17.5 mg) to monthly minodronate (MIN 50 mg) in patients with rheumatoid arthritis (RA).

Methods

Patient characteristics were as follows: n=172; 155 postmenopausal women; age 65.5 (44-87) years; T-score of lumbar spine (LS), -1.4; total hip (TH), -1.8; femoral neck (FN), -2.1; dose and rate of oral prednisolone (2.3 mg/day), 69.1%; prior duration of ALN or RIS, 46.6 months; were allocated, based on their preference, to either the (1) continue group (n=88), (2) switch-from-ALN group (n=44), or (3) switch-from-RIS group (n=40).

Results

After 12 months, increase in BMD was significantly greater in group 3 compared to group 1: LS (4.1 vs 1.2%; $P < 0.001$), TH (1.9 vs -0.7%; $P < 0.01$), and FN (2.7 vs -0.5%; $P < 0.05$); and in group 2 compared to group 1: LS (3.2 vs 1.2%; $P < 0.05$) and TH (1.5 vs -0.7%; $P < 0.01$). The decrease in bone turnover markers was significantly greater in group 3 compared to group 1: TRACP-5b (-37.3 vs 2.5%; $P < 0.001$), PINP

(-24.7 vs -6.2%; $P < 0.05$), and ucOC (-39.2 vs 13.0%; $P < 0.05$); and in group 2 compared to group 1: TRACP-5b (-12.5 vs 2.5%; $P < 0.05$) at 12 months.

Conclusions

Switching weekly ALN or RIS to monthly MIN in patients with RA may be an effective alternative treatment option of oral bisphosphonate treatment.

Keywords

Rheumatoid arthritis; osteoporosis; minodronate; alendronate; risedronate.

Mini Abstract

Switching weekly ALN or RIS to monthly MIN in patients with RA, of whom two-thirds were treated with low-dose PSL, significantly decreased bone turnover markers and increased BMD at 12 months, suggesting that monthly MIN may be an effective alternative treatment option of oral bisphosphonate treatment.

Introduction

Increased risk of fractures in patients with rheumatoid arthritis (RA) compared to non-RA controls has been reported, with risk ratios (RR) varying from 2.0 to 3.0 at the

hip and 2.4 to 6.2 at the spine [1-3]. Pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF- α), interleukin (IL)-1, IL-6, and IL-17, are strongly involved in the pathogenesis of RA, and also concerned with osteoclastogenesis and consequent bone loss [4-7]. Indeed, high bone turnover and inflammation is associated with bone loss of the femoral neck (FN) in postmenopausal RA patients [8]. Moreover, glucocorticoids are often used to treat RA, which induce apoptosis of osteoblasts and osteocytes, and result in increased fracture risk [9, 10]. Minodronate (MIN) is an oral nitrogen-containing bisphosphonate (BP) developed in Japan which has a stronger inhibitory effect on farnesyl pyrophosphate synthase in osteoclasts compared with alendronate (ALN) or risedronate (RIS) [11]. It has been shown that switching daily or weekly BP (mainly ALN and RIS) to monthly MIN increased bone mineral density (BMD) of the lumbar spine (LS) and distal radius, and also decreased bone turnover markers in patients with osteoporosis [12]. There are still considerable number of patients who desire oral osteoporosis treatment, and we hypothesized that MIN can be a convenient candidate of alternative oral BP treatment in patients with RA treated by ALN and RIS, which may be more effective in decreasing bone turnover and increasing BMD. The aim of this prospective study was to clarify the effect of switching weekly ALN (35 mg) or RIS (17.5 mg) to monthly minodronate (50 mg) in patients with RA.

78

79 **Materials and methods**

80 *Study design and subjects*

81 This twelve-month observational study was conducted based on a two-center,
82 prospective, open-label design. A total of 172 patients with RA who were treated with
83 oral weekly ALN or RIS in proportion to the Japanese guidelines for prevention and
84 treatment of osteoporosis 2011 [13] and the guidelines on the management and
85 treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and
86 Mineral Research 2004 [14], were enrolled in the study (Fig. 1). RA was diagnosed
87 based on the 1987 revised American College of Rheumatology (ACR) criteria [15].
88 C-reactive protein (CRP), matrix metalloproteinase-3 (MMP-3), and the Disease
89 Activity Score assessing 28 joints with CRP (DAS28-CRP) were evaluated as the
90 parameters reflecting inflammation as well as the disease activity of RA [16, 17].
91 Registered patients were asked their preference for a change to monthly oral BP
92 treatment and were allocated based on their preferences to either the “continue” group
93 (n=88), consisting of patients who wanted to continue their current therapies, or the
94 “switch-from-ALN” group (n=44) or “switch-from-RIS” group (n=40), consisting of
95 patients who were willing to switch over to MIN 50 mg from their current therapies.

1
2 96 Other combined osteoporosis treatments, such as active vitamin D, vitamin K₂, and
3
4
5 97 **calcium** were continued during the study period. Patients' treatment persistence and
6
7
8 98 satisfaction levels with the therapies were assessed using a self-administered
9
10
11 99 questionnaire at 12 months (Table 1). **Patients were asked for their drug adherence every**
12
13
14 100 **time visiting outpatient clinic (every 1-3 months), and patients who didn't take their**
15
16
17 101 **medications more than twice of their interval (more than 2 weeks for weekly ALN or**
18
19
20 102 **RIS, and more than 2 months for monthly MIN) were considered as drop-out.**

21
22
23
24 103 This observational study was conducted in accordance with the ethical standards of the
25
26
27 104 Declaration of Helsinki and was approved by ethical review boards at the clinical center
28
29
30 105 (approval number 11273-2; Osaka University, Graduate School of Medicine). Written
31
32
33 106 informed consent was obtained from individual patients included in the study.
34
35
36

37 107

38 39 40 108 *BMD assessment*

41
42
43 109 Areal BMD in the LS (L2-L4), total hip (TH), and femoral neck (FN) were assessed by
44
45
46 110 dual-energy x-ray absorptiometry (Discovery A, Hologic, Inc., Waltham, MA, USA) at
47
48
49 111 baseline and after 6 and 12 months of treatment. Regions of severe scoliosis, vertebral
50
51
52 112 fracture, and operated sites were excluded from BMD measurements as previously
53
54
55 113 described [18].
56
57
58
59
60
61
62
63
64
65

114

115 *Biochemical markers of bone turnover*

116 Bone turnover markers were measured in serum obtained from each patient at

117 approximately the same time in the morning after overnight fasting. The bone formation

118 marker, N-terminal type I procollagen propeptide (PINP); inter-assay coefficient of

119 variation (CV), 3.2%-5.2%, (Intact UniQ assay; Orion Diagnostica, Espoo, Finland),

120 and bone resorption marker, isoform 5b of tartrate-resistant acid phosphatase

121 (TRACP-5b); inter-assay CV, 5.0%-9.0%, (Immunodiagnostic Systems Ltd., Boldon,

122 UK) were measured by ELISA as previously described [19]. Levels of

123 undercarboxylated osteocalcin (ucOC) were measured by a solid-phase enzyme

124 immunoassay kit; inter-assay CV, 5.2%-8.3%, (Takara Bio, Shiga, Japan) with a

125 sensitivity of 0.25 ng/mL. **UcOC reflects not only vitamin K deficiency, but also total**

126 **bone turnover, as it is released from both osteoblasts and absorbed bone extracellular**

127 **matrix by osteoclast as previously described [20, 21].** Intact- parathyroid hormone

128 (PTH) was measured using a two-site immunoradiometric assay; inter-assay CV 8.4%,

129 (Nichols Institute Diagnostics, Valencia, USA).

130

131 *Statistical analysis*

The normal distributions of the data were examined by the Shapiro-Wilk test. Differences between each study group were tested using analysis of variance for normally distributed data and the nonparametric Kruskal-Wallis test was used for non-normally distributed data. Changes in BMD and ranked bone turnover marker data from baseline to specified time points within each study group were compared using the nonparametric Wilcoxon signed-rank test. Results are expressed as the mean \pm standard error. A *P* value < 0.05 indicated statistical significance. All tests were performed using IBM SPSS Statistics version 22 software (IBM, Armonk, NY, USA).

Results

Baseline characteristics are shown in Table 2. Of the 172 study patients, 84 (48.8%) were willing to switch to MIN 50 mg. No significant differences were observed in baseline age, combined dose and prescription rate of active vitamin D or vitamin K₂ or calcium or prednisolone (PSL), BMD, or disease activity of RA between the groups.

Duration of prior BP therapy at baseline was significantly longer in the switch-from-ALN group (57.2 months) compared to the continue group (43.6 months; *P* < 0.05) and the switch-from-RIS group (41.0 months; *P* < 0.05). Baseline serum TRACP-5b levels in the switch-from-ALN group were significantly lower compared to

the switch-from-RIS group (244.5 vs 309.8 mU/dL; $P < 0.05$). Eventually, 95.5% (84/88) of patients in the continue group (2 patients were lost to follow up and 2 patients desired to change the medication) and 94.0% (79/84) of patients in the switch group (3 patients were lost to follow up and 2 patients desired to change the medication) completed the twelve-month trial (Fig. 1).

Change in BMD

BMD was monitored every 6 months (Fig. 2). Both the switch groups showed a significant increase in LS and TH BMD from baseline to 6 and 12 months, while only the switch-from-RIS group showed a significant increase in FN BMD from baseline to 6 and 12 months. Moreover, the switch-from-RIS group showed a significantly greater increase compared to the continue group in the LS from 6 months (2.3 vs 0.6%; $P < 0.05$) to 12 months (4.1 vs 1.2%; $P < 0.001$), in the TH from 6 months (1.8 vs -0.5%; $P < 0.01$) to 12 months (2.0 vs -0.7%; $P < 0.01$), and in the FN from 6 months (2.0 vs -0.4%; $P < 0.05$) to 12 months (2.7 vs -0.5%; $P < 0.05$), respectively. On the other hand, the switch-from-ALN group showed a significantly greater increase compared to the continue group in LS BMD at 12 months (3.2 vs 1.2%; $P < 0.05$) and in the TH from 6 months (1.2 vs -0.5%; $P < 0.01$) to 12 months (1.5 vs -0.7%; $P < 0.01$). The

switch-from-RIS group showed a significantly greater increase compared to the switch-from-ALN group in the FN from 6 months (2.1 vs -0.3%; $P < 0.05$) to 12 months (2.7 vs -0.6%; $P < 0.05$).

Bone turnover markers

Percent changes in bone turnover markers from baseline are shown in Fig. 3. The switch-from-RIS group showed a significantly greater decrease compared to the continue group in TRACP-5b levels from 6 months (-35.8 vs 1.3%; $P < 0.001$) to 12 months (-37.3 vs 2.5%; $P < 0.001$), in PINP levels from 6 months (-22.2 vs -3.3%; $P < 0.05$) to 12 months (-24.7 vs -6.2%; $P < 0.05$), and in ucOC levels from 6 months (-22.2 vs 12.4%; $P < 0.05$) to 12 months (-39.2 vs 13.0%; $P < 0.05$). On the other hand, the switch-from-ALN group showed a significantly greater decrease compared to the continue group only in TRACP-5b levels from 6 months (-14.6 vs 1.3%; $P < 0.01$) to 12 months (-12.5 vs 2.5%; $P < 0.05$). The switch-from-RIS group showed a significantly greater decrease than the minimum significant change of serum TRACP-5b, PINP, and ucOC levels, while the switch-from-ALN group showed only in the serum TRACP-5b at 12 months. There were no greater changes than the minimum significant change of serum TRACP-5b, PINP, and ucOC levels in the continue group. The absolute value of

bone turnover markers are shown in Fig. 4. The average value of TRACP-5b, PINP, and ucOC in all the groups were all within the reference value.

Rate of fragility fracture

During the twelve-month period, the continue group patients experienced 3 vertebral and 1 non-vertebral clinical fragility fractures (4.5%). The switch-from-ALN group experienced 1 vertebral and 1 non-vertebral clinical fragility fractures (4.5%), and no clinical fragility fracture was observed in the switch-from-RIS group (0.0%). No statistically significant difference in the total clinical fragility fracture rate was observed between the groups.

Patient preference after switching to MIN 50 mg

Patient preference after switching to monthly MIN 50 mg is shown in Fig. 5. The questionnaire revealed that 80.8% of patients were satisfied with the switch to monthly therapy and 88.7% preferred to continue the monthly treatment. The main reasons for desiring continuation of monthly dosing was both the decreased frequency (69.8%) and less worry about forgetting doses (47.2%), thus a perception of less overall burden.

Discussion

In this study, we have demonstrated for the first time that in patients with RA, of whom two-thirds were treated with low-dose PSL (< 10 mg/day), switching from weekly ALN or RIS to monthly MIN was effective in increasing BMD and decreasing bone turnover markers at 12 months. In addition, no previous studies have demonstrated the difference of the effects of switching, by the difference of prior BP therapies.

In nitrogen-containing BP treatment, mineral binding affinities may influence their distribution within bone and the period till anti-fracture effects are shown, and inhibition of farnesyl diphosphate synthase (FPPS) may affect their anti-resorptive effects by inducing apoptosis of osteoclasts [22].

It has been shown that ALN possesses a stronger binding affinity to hydroxyapatite compared to RIS, while RIS possesses a stronger FPPS inhibition compared to ALN [22]. Consequently, weekly ALN (70 mg) showed a greater increase in BMD and decrease in bone turnover markers compared to weekly RIS (35 mg) in patients with postmenopausal osteoporosis [23], while RIS showed lower rates of hip and non-vertebral fractures than ALN during the first year of therapy [24].

Previous reports have demonstrated that MIN showed stronger FPPS inhibition [11] and a weaker binding affinity to hydroxyapatite compared to ALN and RIS [25], which

1
2 222 suggests that MIN inhibits bone resorption more strongly and is more quickly
3
4
5 223 distributed within the bone compared to ALN and RIS. Indeed, MIN suppressed bone
6
7
8 224 remodeling of cancellous and cortical bone more strongly than ALN in vitro [26], as
9
10
11 225 well as in ovariectomized cynomolgus monkeys in vivo [27]. In the previous human
12
13
14 226 study, switching ALN or RIS to monthly MIN for 6 months increased BMD +1.1% in
15
16
17
18 227 LS, and the reduction rate of serum TRACP-5b was approximately 35% in the
19
20
21 228 switching from RIS group at 6 months [12], which were consistent with our study.
22
23
24 229 Finally, glucocorticoids have been shown to induce apoptosis of osteocytes, and BPs
25
26
27 230 inhibit osteocyte apoptosis in vitro [28] as well as in glucocorticoid-treated animals [29].
28
29
30 231 A systematic review and meta-analysis revealed that BPs can preserve bone mass and
31
32
33 232 reduce the incidence of vertebral fractures in patients with rheumatic disease, mainly for
34
35
36 233 those who are being treated with glucocorticoids [30], and both ALN and RIS strongly
37
38
39 234 decreased the fracture risk associated with glucocorticoid-induced osteoporosis (GIO)
40
41
42 235 [31, 32]. In this study, monthly MIN 50 mg resulted in a greater BMD increase and
43
44
45 236 bone turnover decrease when patients were switched from ALN or RIS, which suggests
46
47
48 237 its effectiveness not only in primary osteoporosis, but also in GIO.
49
50
51 238 There are several limitations to this study. Due to the small number of subjects, fracture
52
53
54 239 risk comparisons should be assessed in a randomized, larger cohort. As most of the
55
56
57
58
59
60
61
62
63
64
65

patients showed remission or low disease activity in this study, the effects of switching on high disease activity patients should be assessed in further study. Although most patients were postmenopausal, some male patients were included in this study. Concerning medication, the dose of ALN and RIS allowed in Japan is the half of Caucasians, and the duration of prior BP therapy was significantly longer in switch-to ALN group compared to other groups. In addition, only a small number of patients were combined with calcium formulation, and total calcium intake couldn't be monitored. In conclusion, switching weekly ALN or RIS to monthly MIN in patients with RA, of whom two-thirds were treated with low-dose PSL, significantly decreased bone turnover markers and increased BMD at 12 months, suggesting that monthly MIN may be an effective alternative treatment option of oral BP treatment.

Acknowledgments

The authors thank Dr. Kenrin Shi for his excellent cooperation in conducting the study.

Authors' roles

Study design: KE, MH, JH, and HY. Study conduct: KE, TN, MH, and SK. Data collection: KE, TN, SK, and MY. Data analysis: KE, TN, and MH. Data interpretation:

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

258 KE and MH. Drafting the manuscript: KE and MH. Approving final version of the
259 manuscript: KE, TN, MH, JH, SK, and HY. KE takes responsibility for the integrity of
260 the data analysis.

261

262 **Conflicts of interest**

263 This research was funded by Astellas Pharma, Inc. The funder had no role in the study
264 design, data collection, data analysis, decision to publish, or preparation of the
265 manuscript. Kosuke Ebina, Takaaki Noguchi, Makoto Hirao, Jun Hashimoto, Shoichi
266 Kaneshiro, Masao Yukioka, and Hideki Yoshikawa declare that they have no conflict of
267 interest.

References

1. Peel NF, Moore DJ, Barrington NA, Bax DE, Eastell R (1995) Risk of vertebral fracture and relationship to bone mineral density in steroid treated rheumatoid arthritis. *Ann Rheum Dis* 54:801-806
2. van Staa TP, Geusens P, Bijlsma JW, Leufkens HG, Cooper C (2006) Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. *Arthritis Rheum* 54:3104-3112
3. Wright NC, Lisse JR, Walitt BT, Eaton CB, Chen Z (2011) Arthritis increases the risk for fractures--results from the Women's Health Initiative. *J Rheumatol* 38:1680-1688
4. Braun T, Schett G (2012) Pathways for bone loss in inflammatory disease. *Curr Osteoporos Rep* 10:101-108
5. Ebina K, Oshima K, Matsuda M, et al. (2009) Adenovirus-mediated gene transfer of adiponectin reduces the severity of collagen-induced arthritis in mice. *Biochem Biophys Res Commun* 378:186-191
6. Kaneshiro S, Ebina K, Shi K, Higuchi C, Hirao M, Okamoto M, Koizumi K, Morimoto T, Yoshikawa H, Hashimoto J (2014) IL-6 negatively regulates osteoblast differentiation through the SHP2/MEK2 and SHP2/Akt2 pathways in vitro. *J Bone Miner Metab* 32:378-392
7. Noguchi T, Ebina K, Hirao M, et al. (2015) Progranulin plays crucial roles in preserving bone mass by inhibiting TNF-alpha-induced osteoclastogenesis and promoting osteoblastic differentiation in mice. *Biochem Biophys Res Commun* 465:638-643
8. Cortet B, Guyot MH, Solau E, Pigny P, Dumoulin F, Flipo RM, Marchandise X, Delcambre B (2000) Factors influencing bone loss in rheumatoid arthritis: a longitudinal study. *Clin Exp Rheumatol* 18:683-690
9. Kanis JA, Johansson H, Oden A, et al. (2004) A meta-analysis of prior corticosteroid use and fracture risk. *J Bone Miner Res* 19:893-899
10. Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C (2000) Use of oral corticosteroids and risk of fractures. *J Bone Miner Res* 15:993-1000
11. Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ (2001) Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. *J Pharmacol Exp Ther* 296:235-242
12. Sakai A, Ikeda S, Okimoto N, et al. (2014) Clinical efficacy and treatment persistence of monthly minodronate for osteoporotic patients unsatisfied with, and shifted from, daily or

weekly bisphosphonates: the BP-MUSASHI study. *Osteoporos Int* 25:2245-2253

13. Orimo H, Nakamura T, Hosoi T, et al. (2012) Japanese 2011 guidelines for prevention and treatment of osteoporosis--executive summary. *Arch Osteoporos* 7:3-20

14. Nawata H, Soen S, Takayanagi R, et al. (2005) Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research (2004). *J Bone Miner Metab* 23:105-109

15. Arnett FC, Edworthy SM, Bloch DA, et al. (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis Rheum* 31:315-324

16. Ebina K, Shi K, Hirao M, Kaneshiro S, Morimoto T, Koizumi K, Yoshikawa H, Hashimoto J (2013) Vitamin K2 administration is associated with decreased disease activity in patients with rheumatoid arthritis. *Mod Rheumatol* 23:1001-1007

17. Matsui T, Kuga Y, Kaneko A, Nishino J, Eto Y, Chiba N, Yasuda M, Saisho K, Shimada K, Tohma S (2007) Disease Activity Score 28 (DAS28) using C-reactive protein underestimates disease activity and overestimates EULAR response criteria compared with DAS28 using erythrocyte sedimentation rate in a large observational cohort of rheumatoid arthritis patients in Japan. *Ann Rheum Dis* 66:1221-1226

18. Ebina K, Noguchi T, Hirao M, Kaneshiro S, Tsukamoto Y, Yoshikawa H (2015) Comparison of the effects of 12 months of monthly minodronate monotherapy and monthly minodronate combination therapy with vitamin K or eldecacitol in patients with primary osteoporosis. *J Bone Miner Metab*

19. Ebina K, Hashimoto J, Shi K, Kashii M, Hirao M, Yoshikawa H (2014) Comparison of the effect of 18-month daily teriparatide administration on patients with rheumatoid arthritis and postmenopausal osteoporosis patients. *Osteoporos Int* 25:2755-2765

20. Booth SL, Centi A, Smith SR, Gundberg C (2013) The role of osteocalcin in human glucose metabolism: marker or mediator? *Nat Rev Endocrinol* 9:43-55

21. Ebina K, Hashimoto J, Shi K, Kashii M, Hirao M, Yoshikawa H (2014) Undercarboxylated osteocalcin may be an attractive marker of teriparatide treatment in RA patients: response to Mokuda. *Osteoporos Int*

22. Russell RG, Watts NB, Ebtino FH, Rogers MJ (2008) Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. *Osteoporos Int* 19:733-759

23. Reid DM, Hosking D, Kendler D, et al. (2008) A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24-month results from FACTS-International. *Int J Clin Pract* 62:575-584

24. Silverman SL, Watts NB, Delmas PD, Lange JL, Lindsay R (2007) Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the

risedronate and alendronate (REAL) cohort study. *Osteoporos Int* 18:25-34

25. Ebtino FH, Hogan AM, Sun S, et al. (2011) The relationship between the chemistry and biological activity of the bisphosphonates. *Bone* 49:20-33

26. Tsubaki M, Komai M, Itoh T, et al. (2014) Nitrogen-containing bisphosphonates inhibit RANKL- and M-CSF-induced osteoclast formation through the inhibition of ERK1/2 and Akt activation. *J Biomed Sci* 21:10

27. Yamagami Y, Mashiba T, Iwata K, Tanaka M, Nozaki K, Yamamoto T (2013) Effects of minodronic acid and alendronate on bone remodeling, microdamage accumulation, degree of mineralization and bone mechanical properties in ovariectomized cynomolgus monkeys. *Bone* 54:1-7

28. Plotkin LI, Manolagas SC, Bellido T (2006) Dissociation of the pro-apoptotic effects of bisphosphonates on osteoclasts from their anti-apoptotic effects on osteoblasts/osteocytes with novel analogs. *Bone* 39:443-452

29. Follet H, Li J, Phipps RJ, Hui S, Condon K, Burr DB (2007) Risedronate and alendronate suppress osteocyte apoptosis following cyclic fatigue loading. *Bone* 40:1172-1177

30. Feng Z, Zeng S, Wang Y, Zheng Z, Chen Z (2013) Bisphosphonates for the prevention and treatment of osteoporosis in patients with rheumatic diseases: a systematic review and meta-analysis. *PLoS One* 8:e80890

31. Adachi JD, Saag KG, Delmas PD, et al. (2001) Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. *Arthritis Rheum* 44:202-211

32. Wallach S, Cohen S, Reid DM, et al. (2000) Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. *Calcif Tissue Int* 67:277-285

Figure legends

Figure 1. Study design and schedule. Patients were asked for their willingness to switch to monthly MIN 50 mg. Bone mineral density and bone turnover markers were evaluated every 6 months in all the patients. The switch group patients were asked to complete a patient preference questionnaire at 12 months.

Figure 2. Mean \pm standard error (SE) change from baseline in bone mineral density (BMD) at the lumbar spine (panel a), total hip (panel b), and femoral neck (panel c). * P < 0.05, ** P < 0.01, *** P < 0.001 change from baseline within each treatment group. # P < 0.05, ## P < 0.01, ### P < 0.001 continue group versus switch-from-RIS group. † P < 0.05, switch-from-ALN group versus switch-from-RIS group.

Figure 3. Mean \pm standard error (SE) change from baseline in serum concentration of bone turnover markers TRAP-5b (panel a), PINP (panel b), and ucOC (panel c). TRAP-5b, isoform 5b of tartrate-resistant acid phosphatase; PINP, type I collagen N-terminal propeptide; ucOC, undercarboxylated osteocalcin; # P < 0.05, ## P < 0.01, ### P < 0.001 continue group versus each switch group. * P < 0.05, ** P < 0.01

switch-from-ALN group versus switch-from-RIS group.

Figure 4. Mean \pm standard error (SE) absolute value of bone turnover markers TRAP-5b (panel a), PINP (panel b), and ucOC (panel c). TRAP-5b, isoform 5b of tartrate-resistant acid phosphatase; PINP, type I collagen N-terminal propeptide; ucOC, undercarboxylated osteocalcin; $^{\#}P < 0.05$, $^{\#\#}P < 0.01$, $^{\#\#\#}P < 0.001$ continue group versus each switch group. $^*P < 0.05$ switch-from-ALN group versus switch-from-RIS group.

Figure 5. Patient satisfaction, preference, and reasons for preference after switching weekly ALN or RIS to monthly MIN 50 mg treatment at 12 months.

1 Table 1. Patient preference questionnaire

1.	Rate your satisfaction with the current once-monthly dosing schedule ^{a)}				
	1	2	3	4	5
	1-Low satisfaction 5-High satisfaction				
2.	Which dosing schedule do you prefer?				
	a. Once weekly b. Once monthly c. No preference				
3.	If you prefer once-monthly dosing schedule, check all the statements you agree with ^{b)}				
	a. This dosing schedule impose less burden of frequency				
	b. This dosing schedule has less worry to forget				
	c. I feel this dosing schedule is more effective				
	d. I expect less side effects with this dosing schedule				
	e. Others				

2 a) Answer 4 and 5 are evaluated as satisfied, 3 as no preference, and 1 and 2 as not satisfied.

3 b) Multiple answers allowed.

4

5

6

7

8

9

10

11

12

13

14

15 Table 2. Baseline clinical characteristics

Variable	Continue (n=88)	Switch-from-ALN (n=44)	Switch-from-RIS (n=40)
Age, (mean \pm SE years)	64.9 \pm 0.9	64.9 \pm 1.6	67.3 \pm 1.6
Gender, Females (%)	81/88 (92.0%)	40/44 (90.9%)	38/40 (95.0%)
Postmenopausal, n/N (%)	80/88 (90.9%)	38/44 (86.4%)	37/40 (92.5%)
Body mass index (kg/m ²)	21.9 \pm 0.4	21.2 \pm 0.6	22.2 \pm 0.6
Prior BP, ALN n/N(%)	58/88 (65.9%)		
Duration of prior BP therapy (months)	43.6 \pm 2.1	57.2 \pm 4.6*	41.0 \pm 5.5 [†]
Combined vitamin D, n/N(%)	46/88 (52.3%)	26/44 (59.1%)	25/40 (62.5%)
Combined vitamin K ₂ , n/N(%)	21/88 (23.9%)	12/44 (27.3%)	10/40 (25.0%)
Combined calcium, n/N(%)	5/88 (5.7%)	3/44 (6.8%)	3/40 (7.5%)
Prior vertebral fracture(s), n/N(%)	25/88 (28.4%)	9/44 (20.5%)	8/40 (20.0%)
Prior non-vertebral fracture(s), n/N(%)	22/88 (25.0%)	10/44 (22.7%)	7/40 (17.5%)
Bone mineral density (BMD)			
Lumbar spine BMD (g/cm ²)	0.856 \pm 0.017	0.861 \pm 0.028	0.858 \pm 0.019
Lumbar spine BMD (T-score)	-1.4 \pm 0.1	-1.3 \pm 0.2	-1.4 \pm 0.2
Femoral neck BMD (g/cm ²)	0.584 \pm 0.027	0.546 \pm 0.015	0.584 \pm 0.016
Femoral neck BMD (T-score)	-2.1 \pm 0.1	-2.3 \pm 0.1	-2.0 \pm 0.1
Total hip BMD (g/cm ²)	0.698 \pm 0.028	0.658 \pm 0.017	0.677 \pm 0.018
Total hip BMD (T-score)	-1.8 \pm 0.1	-1.9 \pm 0.1	-1.8 \pm 0.2
T-score < -2.5, n/N(%)	45/88 (51.1%)	22/44 (50.0%)	16/40 (40.0%)
PINP (μ g/l)	34.2 \pm 2.7	29.7 \pm 2.7	34.5 \pm 2.5
TRACP-5b (mU/dl)	258.1 \pm 11.2	244.5 \pm 17.6	309.8 \pm 22.7 [†]
ucOC (ng/ml)	2.7 \pm 0.3	3.6 \pm 0.9	3.7 \pm 0.6
Intact-PTH (pg/ml)	48.9 \pm 2.4	51.5 \pm 3.7	45.6 \pm 2.6
eGFR (ml/min/1.73m ²)	77.2 \pm 2.5	73.6 \pm 3.5	74.9 \pm 3.3
Duration of disease (years)	17.6 \pm 1.0	18.3 \pm 1.6	15.1 \pm 1.5
RF positivity, n/N (%)	73/88 (83.0%)	41/44(93.2%)	35/40(87.5%)
ACPA positivity, n/N (%)	75/88 (85.2%)	40/44(90.9%)	34/40(85.0%)
CRP (mg/dl)	0.7 \pm 0.1	0.6 \pm 0.1	0.5 \pm 0.1
MMP-3 (ng/ml)	158.4 \pm 16.2	118.1 \pm 16.4	118.2 \pm 30.1

DAS28-CRP	2.6±0.1	2.5±0.1	2.4±0.1
Remission (< 2.3), n/N (%)	41/88 (46.6%)	22/44 (50.0%)	22/40 (55.0%)
Low disease activity (< 2.7), n/N (%)	16/88 (18.2%)	11/44 (25.0%)	7/40 (17.5%)
Moderate disease activity (2.7 -4.1), n/N (%)	26/88 (29.5%)	10/44 (22.7%)	9/40 (22.5%)
High disease activity (> 4.1), n/N (%)	5/88 (5.7%)	1/44 (2.3%)	2/40 (5.0%)
MHAQ	0.5±0.1	0.4±0.1	0.6±0.1
Prednisolone dose (mg/day)	2.5±0.3	2.2±0.3	1.7±0.4
Prednisolone usage, n/N(%)	62/88 (70.5%)	32/44 (72.7%)	25/40 (62.5%)
MTX dose (mg/week)	5.0±0.4	5.6±0.6	4.7±0.6
MTX usage, n/N (%)	63/88 (71.6%)	35/44(79.5%)	28/40(70.0%)
Biologics usage, n/N (%)	20/88 (25.7%)	8/44(18.2%)	9/40(22.5%)


Mean ± Standard Error (SE), unless otherwise noted.




n/N (%) = number of patients with measurements / total number of patients (%)

ALN, Alendronate; RIS, Risedronate; BP, Bisphosphonate; PINP, Type I collagen N-terminal propeptide; TRAP-5b, Isoform 5b of tartrate-resistant acid phosphatase; ucOC, Undercarboxylated osteocalcin; PTH, parathyroid hormone; eGFR, Estimated glomerular filtration rate; RF, Rheumatoid factor; ACPA, Anti-cyclic citrullinated peptide antibody; CRP, C-reactive protein; MMP-3, Matrix metalloproteinase-3; DAS28-CRP, Disease activity score assessing 28 joints with CRP; MHAQ, Modified Health Assessment Questionnaire; MTX, Methotrexate.


Differences between the groups were determined by ANOVA or chi-square test. *P<0.05 vs Continue group. **P<0.01 vs Continue group. †P<0.05 vs Switch-from-ALN group. ††P<0.01 vs Switch-from-ALN group.

Figure







a



b




c



a

TRACP-5b


reference range: 120-420 mU/dl



b

PINP


reference range: 14.9-68.8 µg/l




c

UcOC


reference range: <4.5 ng/ml



a



b



c

